A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

NCT07738510 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Anemia

Interventions

DRUG: Ofirnoflast

Sponsor

Halia Therapeutics, Inc.

Collaborators

[object Object]